tumor-pulsed dendritic cells
Vaccineexperimental
Clinical trial activity
64 trials · 65 clinical orgs · 0 marketing orgs
Phase 1
37
Phase 2
46
Phase 3
6
Phase 4
0
Earliest trial started Nov 3, 2000 (NCT00006434)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Brain Neoplasms · Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Chemotherapy, Adjuvant · Phase 2
- Colorectal Neoplasms · Phase 2
- Dendritic Cells · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioblastoma · Phase 3
- Glioma · Phase 3
- Gliosarcoma · Phase 2
- Hamartoma · Phase 2
- HIV · Phase 1
- HIV Infections · Phase 1/Phase 2
- Leukemia · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Melanoma · Phase 3
- Mesothelioma, Malignant · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2/Phase 3
- Neoplasms, Connective and Soft Tissue · Phase 1/Phase 2
- Neuroblastoma · Phase 2
- Oligodendroglioma · Phase 2
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2/Phase 3
- Prostatic Neoplasms · Phase 3
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 1
- Sarcoma, Synovial · Phase 1
- Sepsis · Phase 2
- Sezary Syndrome · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 2
- Vaccination · Phase 2
- Wilms Tumor · Phase 2
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous dendritic cell cancer vaccine
- autologous dendritic cells loaded with autologous tumor rna
- autologous dendritic cells loaded with autologous tumour homogenate
- autologous dendritic cells pulsed with tumor lysate antigen vaccine
- autologous dendritic cell-tumor cell
- autologous dendritic cell vaccine
- autologous tumor lysate, particle-loaded, dendritic cells
- autologous tumor lysate-pulsed dendritic cells
- cancer stem cell stimulated dendritic cells
- dendritic cell-based tumor vaccine
- dendritic cells pulsed with tumor lysate
- dendritic cell vaccine
- leukemic dendritic cell vaccine
- malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine
- personalized mature dendritic cell vaccine
- tumor antigen loaded autologous dendritic cells
- tumor antigen-loaded dendritic cell-derived exosomes
- tumor lysate-loaded autologous dendritic cells
- tumor lysate, particle loaded, dendritic cells
- tumor lysate-pulsed autologous dendritic cell vaccine
- tumor lysate-pulsed dendritic cells
- tumor-lysate pulsed dendritic cells
- tumor lysate-pulsed dendritic cell vaccine
- tumor peptide-loaded myeloid dendritic cells
- tumor peptide-loaded plasmacytoid dendritic cells
- tumor-pulsed dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05955157 | Phase 2/Phase 3 (Phase 3) | Jan 3, 2023 | University of Malaya |
| NCT04199559 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2019 | Henan Medical University, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT03360708 | Early Phase 1 (Phase 1) | Nov 30, 2018 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03395587 | Phase 2 | Mar 6, 2018 | German Federal Ministry of Education and Research, University of Duesseldorf |
| NCT03185429 | Phase 1 | Dec 1, 2017 | BGI Group, Fujian Medical University |
| NCT03014804 | Phase 2 | Aug 1, 2017 | Bristol-Myers Squibb, National Cancer Institute (NCI), Northwest Biotherapeutics, University of California, Los Angeles |
| NCT03410732 | Phase 2 | Jul 1, 2017 | LanZhou University |
| NCT03114631 | Phase 1/Phase 2 (Phase 2) | Jan 9, 2017 | Belarusian State Medical University, The Republican Center for Research and Practice in Otolaryngology, Belarus, The Republican Research and Practical Center for Epidemiology and Microbiology |
| NCT02419170 | Early Phase 1 (Phase 1) | Jul 1, 2016 | Washington University in St. Louis |
| NCT02033616 | Phase 2 | Jul 1, 2016 | Caladrius Biosciences |
| NCT02919644 | Phase 2 | Apr 1, 2016 | Istituto Nazionale per lo Studio e la Cura dei Tumori |
| NCT02678741 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Cancer Insight, LLC, Elios Therapeutics, LLC |
| NCT02649582 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | University of Antwerp |
| NCT02574377 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Radboud University |
| NCT02632019 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Eastern Hepatobiliary Surgery Hospital, People's Liberation Army of China |
| NCT02548169 | Phase 1 | Aug 1, 2015 | Baylor University, Charles A. Sammons Cancer Center/Texas Oncology |
| NCT02718391 | Phase 2 | Aug 1, 2015 | Istituto Nazionale per lo Studio e la Cura dei Tumori |
| NCT02301611 | Phase 2 | Jan 1, 2015 | Cancer Insight, LLC, Elios Therapeutics, LLC |
| NCT01875653 | Phase 3 | Oct 1, 2014 | Caladrius Biosciences |
| NCT02178670 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Jinan University, University of Michigan |
Showing 20 of 64 trials
Page 1 / 4
Organizations
Research & Development (65)
65 organizations
Page 1 / 4